Feature Reports

Innovation in oncology continues to accelerate, with global cancer R&D spending now exceeding hundreds of billions annually and more than a thousand new trials launched each year. Among the fastest-growing segments is radiopharmaceuticals, attracting significant investment as major pharmaceutical companies expand into precision radiation therapies. Growth has been fueled by strong clinical performance, improving isotope… Continue reading Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins European Phase 1 Trial of Nectin-4 Targeted Alpha Therapy for Multiple Solid Tumors

Retail trading has emerged as a powerful force in global markets, with participation rising from roughly 25% of all trading activity in 2020 to over 30% by 2024. This surge has driven growing demand for social investing tools, copy trading features, and automated strategies, with analysts projecting these platforms could generate several billion dollars in… Continue reading FDCTech, Inc. (OTC: FDCT) Poised to Capitalize on the Retail Trading Boom

Targeted radiotherapy has become one of the hottest areas in oncology, driving more than $30 billion in pharma deals over the past three years. Prostate, lung, and breast cancer alone account for over $60 billion in annual drug spending, yet resistance to current therapies continues to create costly failures. Actinium Pharmaceuticals (NYSE American: ATNM) is… Continue reading Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is expanding its radiotherapeutic platform beyond hematologic cancers with ATNM-400, a next-generation candidate designed to deliver targeted radiation against B7-H3, an immune-checkpoint molecule highly expressed across multiple solid tumors. B7-H3 overexpression is linked to tumor aggressiveness, immune evasion, and treatment resistance, making it an increasingly important target. By pairing… Continue reading ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa           

Skin cancer is the most common cancer in the U.S., with more than five million non-melanoma cases, overwhelmingly basal cell carcinomas, diagnosed annually. Aging populations, increased sun exposure, and rising detection rates are driving demand for treatment. Against this backdrop, Medicus Pharma (NASDAQ: MDCX) emerges as a compelling small-cap opportunity. The company is developing SkinJect(TM),… Continue reading Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch  

Artificial intelligence is transforming how investors interpret markets, but one area is quickly emerging as the new frontier: real-time sentiment analytics linked directly to investor-focused media. With the AI-driven financial analytics market projected to reach $28 billion by 2029, demand is shifting toward platforms that can combine behavioral signals, predictive modeling, and continuous data inputs… Continue reading Aether Holdings, Inc. (NASDAQ: ATHR) Targets $28B AI Analytics Market With a Data-Media Ecosystem Strategy

The drone surveying market is expected to continue to gain momentum due to increasing demand for aerial intelligence and high-precision mapping across major sectors such as agriculture, mining, construction, and environmental monitoring. Fact.MR analysis indicates that the industry will be valued at USD 1.97 billion in 2025 and grow to USD 11.49 billion by 2035,… Continue reading Drone Surveying Set to Grow from $1.97B to $11.49B by 2035 as ZenaTech, Inc. (NASDAQ: ZENA) Expands Its U.S. Footprint

Autonomous technology is shifting from concept to necessity. Global defense spending on unmanned and AI-driven systems is projected to exceed $200 billion by 2030, reflecting how militaries are rethinking strategy for an era where machines interpret data faster than humans can react. Commercial interest is rising too, with AI-powered drones transforming industries from energy to… Continue reading ZenaTech (Nasdaq: ZENA) Emerges at the Crossroads of Defense, AI, and Quantum Computing

The electric vehicle revolution has moved from hype to hard reality, and the next bottleneck is no longer production but power. Global EV sales are expected to exceed 17 million units in 2025, and by 2030, more than 40 percent of new vehicles sold could be electric. That growth will push the EV infrastructure market… Continue reading From Gridlock to Grid Intelligence: How U Power (NASDAQ: UCAR) Is Rewiring the EV Ecosystem

Skin cancer has become one of the fastest-growing cancers worldwide, with tens of millions of new cases diagnosed each year. Yet the standard treatment for basal cell carcinoma (BCC), the most common form of skin cancer, remains surgical removal. Surgery is effective but costly, can leave scars, and often must be repeated for patients who… Continue reading Medicus Pharma Ltd. (NASDAQ: MDCX) and the Patch That Could End Repetitive Cancer Surgeries